Arcturus Therapeutics Holdings Inc. - MarketWatch

6 days ago · 3.51%. $1.46B. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

CouponFollow Extension

51%
OFF

Arcturus Therapeutics Holdings Inc. - MarketWatch

1 week from now

6 days ago · 3.51%. $1.46B. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

marketwatch.com

67%
OFF

Arcturus Therapeutics Holdings Inc. (ARCT) - Yahoo Finance

1 week from now

VCYT Veracyte, Inc. 38.24. -1.67%. AXSM Axsome Therapeutics, Inc. 99.49. Find the latest Arcturus Therapeutics Holdings Inc. (ARCT) stock quote, history, news and other vital …

yahoo.com

6%
OFF

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares

1 week from now

1 day ago · Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 45.6% in the 3rd quarter, according to the …

marketbeat.com

02%
OFF

ARCT - Arcturus Therapeutics Holdings Inc Stock Price Forecast …

1 week from now

The Arcturus Therapeutics Holdings Inc (ARCT) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $37.79, representing a +97.02% …

stockscan.io

$0.26
OFF

Arcturus Therapeutics (ARCT) Earnings Date And Reports 2024

1 week from now

2 days ago · Arcturus Therapeutics Latest Earnings Summary. Arcturus Therapeutics released Q3 2024 earnings on November 7, 2024, reporting an EPS of -$0.26, which beat the consensus …

marketbeat.com

$294
OFF

Arcturus Therapeutics Holdings Inc (ARCT) Q3 2024 Earnings Call ...

1 week from now

Nov 8, 2024 · Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) has a strong financial position with cash, cash equivalents, and restricted cash totaling $294.1 million as of …

yahoo.com

$0.50
OFF

Arcturus Therapeutics Holdings Inc. Analyst Estimates - MarketWatch

1 week from now

Current. -$0.50. 1 Month Ago. -$0.50. 3 Months Ago. $0.14. Arcturus Therapeutics Holdings Inc. analyst estimates, including ARCT earnings per share estimates and analyst recommendations.

marketwatch.com

FAQs about Arcturus Therapeutics Holdings Inc. - MarketWatch Coupon?

Where is Arcturus Therapeutics headquartered?

Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA. ARCT | Complete Arcturus Therapeutics Holdings Inc. stock news by MarketWatch. ...

When is Arcturus Therapeutics's next earnings date?

Arcturus Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off prior year's report dates. When is Arcturus Therapeutics's earnings date? ...

How much does Arcturus Therapeutics (Arcturus) earn per share?

Arcturus Therapeutics has generated $4.05 earnings per share over the last year ($4.05 diluted earnings per share) and currently has a price-to-earnings ratio of 7.1. Earnings for Arcturus Therapeutics are expected to decrease in the coming year, from ($2.62) to ($6.25) per share. ...

What is Arcturus' product pipeline?

Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. ...

What risks should investors consider before investing in Arcturus Therapeutics?

This is broken down into $39.1 million in R&D expenses and then $13.3 million in G&A expenses. There are several risks that investors should be aware of before investing in Arcturus Therapeutics. The first risk to consider would be with respect to the development of LUNAR-CF for the treatment of patients with Cystic Fibrosis. ...

Why should investors care about Arcturus?

Why investors should care now is because Arcturus was given clearance by the FDA to initiate a phase 2 multidose portion of the trial, which will allow for multiple doses over a longer treatment duration. ...